Medical Advocates
HIV Infection/Disease
 
Facial Lipoatrophy Injection Treatment
 
 
General Reports
Calcium Hydroxylapatite
 Fat
Hyaluronic Acid
Polylactic Acid
Polyalkylimide Gel
Polymethyl Methacrylate
Silicone
 Videos
 

 
HIV Facial Lipoatrophy Treament   Main New/Newsworthy Home Page  
Last Update:
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
       
         Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT PDF ARTICLE
 A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of use.
Duracinsky M, Leclercq P, Armstrong AR, et al
BMC Infect Dis. 2013 Feb 20;13(1):92.
 Paper

Treatment of facial lipoatrophy by lipofilling in HIV infected patients: Retrospective study on 317 patients on 9 years.
 Uzzan C, Boccara D, Lacheré A, et al
Ann Chir Plast Esthet. 2012 Jan 2
 Abstract

Comparison Between Lipofilling and a Nonabsorbable Filler for Facial Wasting Rehabilitation in|
HIV-Positive Patients.
 Rauso R, Curinga G, Santillo V, Corvo G, Tartaro G.
J Craniofac Surg. 2011 Sep;22(5):1684-8
 Abstract

Calcium Hydroxylapatite
       
         Journal Papers, Abstracts, and Commentaries
 
  Safety and efficacy of one-step rehabilitation of human immunodeficiency virus-related facial lipoatrophy using an injectable calcium hydroxylapatite dermal filler.
Rauso R, Curinga G, Rusciani A,  et aL
 Dermatol Surg. 2013 Dec;39(12):1887-94. .
 Abstract

Calcium Hydroxylapatite for Facial Rejuvenation.
 Berlin A, Cohen JL, Goldberg DJ.  
 Semin Cutan Med Surg. 2006 Sep;25(3):132-137.
 Abstract

Fat  

       

        Journal Papers, Abstracts, and Commentaries
 
  Treatment of facial fat atrophy related to treatment with protease inhibitors by
"autologous fat injection in patients with human immunodeficiency virus infection.
Serra-Renom JM, Fontdevila J. 
Plast Reconstr Surg. 2004 Aug;114(2):551-5.
 Abstract
 
Treatment of human immunodeficiency virus-associated lipodystrophy with
dermafat graft transfer to the malar area.
Strauch B, Baum T, Robbins N.
 Plast Reconstr Surg. 2004 Jan;113(1):363-70
 Abstract

Hyaluronic Acid

       
          Journal Papers, Abstracts, and Commentaries
 
  Safety and Efficacy of a Volumizing Hyaluronic Acid Filler for Treatment of HIV-Associated Facial Lipoatrophy.
Ho D, Jagdeo J.  
JAMA Dermatol. 2016 Nov 2.
 Abstract

High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy.
Pignatti M, Pedone A, Baccarani A, et al A
esthetic Plast Surg. 2011 Jun 30..
 Abstract

Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients.
Bugge H, Negaard A, Skeie L, Bergersen B.
HIV Med. 2007 Nov;8(8):475-82.
 Abstract

Polylactic Acid
       

               Journal Papers, Abstracts, and Commentaries
 
 
Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial
Lafaurie M, Dolivo M, Girard PM,  et al
HIV Med. 2013 Feb 24.
Abstract

Late-Onset Immune-Mediated Adverse Effects after Poly-L-Lactic Acid Injection in
Non-HIV Patients: Clinical Findings and Long-Term Follow-Up.
lijotas-Reig J, Garcia-Gimenez V, Vilardell-Tarres M.
Dermatology. 2009 Oct 1
 Abstract

Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: A prospective 3-year
follow-up study.
Levy RM, Redbord KP, Hanke CW.
J Am Acad Dermatol. 2008 Dec;59(6):923-933.
 Abstract
 
Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+
patients under tritherapy.
Piquet M, Brignol L, Chatelain B, Rey D, et al 
Rev Stomatol Chir Maxillofac. 2007 Jul 31;
Abstract
 
Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial
lipoatrophy.
Moyle G, Brown S, Lysakova L, Barton S.
HIV Med. 2006 Apr;7(3):181-5.
 Abstract
 
Use of polylactic Acid implants to correct facial lipoatrophy in human immunodeficiency
virus 1-positive individuals receiving combination antiretroviral therapy.
 Cattelan AM, Bauer U, Trevenzoli M, et al
Arch Dermatol. 2006 Mar;142(3):329-34. R
 Abstract
 
Deep Subcutaneous Application of Poly-L-Lactic Acid as a Filler for Facial Lipoatrophy in
HIV-Infected Patients.
 Borelli C, Kunte C, Weisenseel P, et al
Skin Pharmacol Physiol. 2005 Aug 19;18(6):273-278
 Abstract
 
Poly-L-lactic Acid as a facial filler.
Sterling JB, Hanke CW.
Skin Therapy Lett. 2005 Jun;10(5):9-11.
 Abstract
 
Treatment of Facial Lipoatrophy With Intradermal Injections of Polylactic Acid in
HIV-Infected Patients.
 Lafaurie M, Dolivo M, Porcher R, et al  
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):393-398.
 Abstract
 
Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-
associated facial lipoatrophy.
 Burgess CM, Quiroga RM.  
J Am Acad Dermatol. 2005 Feb;52(2 Pt1):233-9
 Abstract

A randomized open-label study of immediate versus delayed polylactic acid
injections for the cosmetic management of facial lipoatrophy in persons with
HIV infection.
 Moyle G, Lysakova L, Brown S, et aL 
HIV Med. 2004 Mar;5(2):82-87.
 Abstract
 
  Polylactic acid implants (New-Fill)(R) to correct facial lipoatrophy in HIV-infected
patients: results of the open-label study VEGA.
Valantin MA, Aubron-Olivier C, Ghosn J, et al 
AIDS. 2003 Nov 21;17(17):2471-7
 Abstract
 
 

Polyalkylimide Gel

       
              Journal Papers, Abstracts, and Commentaries
 
  5-Year Study of a Polyacrylamide Hydrogel-Based Filler for Rehabilitation of HIV-Related Facial Lipoatrophy.
Rauso R.
 Aesthet Surg J. 2015 May 7.
 Abstract

Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial
Lafaurie M, Dolivo M, Girard PM,  et al
HIV Med. 2013 Feb 24.
Abstract

Polyacrylamide Hydrogel Injection in the Management of Human Immunodeficiency
Virus-Related Facial Lipoatrophy: Results of the LIPOPHILL Open-Label Study.
Mole B, Gillaizeau F, Carbonnel E, Pierre I,
AIDS Res Hum Retroviruses. 2011 Aug 30.
 Abstract

Polyacrylamide Gel Injection for Treatment of Human Immunodeficiency Virus-Associated Facial
Lipoatrophy: 18 Months Follow-Up.
Rauso R, Freda N, Parlato V, et al
Dermatol Surg. 2011 Aug 1
 Abstract

Long-Term Effect of Polyalkylimide Gel Injections on Severity of Facial Lipoatrophy and Quality of Life of
HIV-Positive Patients.
Kari.m RB, de Lint CA, van Galen SR, et al
 Aesthetic Plast Surg. 2008 Jun 13
 Abstract
 

Polymethyl Methacrylate
       

              Journal Papers, Abstracts, and Commentaries
 
  Treatment of facial lipoatrophy with polymethylmethacrylate among patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): impact on the quality of life.
Quintas RC, de França ER, de Petribú KC,et al
Int J Dermatol. 2014 Mar 6. .
 Abstract

The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients
as measured by four quality-of-life questionnaires.
Warde M, Gragnani A, Gomes H,
Int J STD AIDS. 2011 Oct;22(10):596-9..
 Abstract

Silicone
       

              Journal Papers, Abstracts, and Commentaries
 
  HIV-associated facial lipoatrophy treated with injectable silicone oil: A pilot study.
Chen F, Carruthers A, Humphrey S, Carruthers J.
 J Am Acad Dermatol. 2013 May 24.
 Abstract

A Case of HIV-Associated Facial Lipoatrophy Treated With 1000-cs Liquid
Injectable Silicone.
Orentreich D, Leone AS.
Dermatol Surg. 2004 Apr;30(4):548-51.
 Abstract

HIV Facial Lipoatrophy Treament   Main New/Newsworthy Home Page  

Facial Lipoatrophy Injection Treatment